You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial

 

Online download statistics by month:

Online download statistics by month: February 2023 to July 2025

AbstractFullPdf
Feb 2023403405140
Mar 2023264267147
Apr 2023172172102
May 202310910960
Jun 202312212358
Jul 202312512567
Aug 202316816781
Sep 202315915975
Oct 202312412468
Nov 202314714756
Dec 202315215391
Jan 2024151151121
Feb 2024909054
Mar 2024121121116
Apr 202411411593
May 2024777758
Jun 202411411396
Jul 202414014398
Aug 202410810765
Sep 202412312580
Oct 2024999967
Nov 202412412779
Dec 202416116677
Jan 202511111184
Feb 2025300300106
Mar 2025142145110
Apr 2025195195115
May 2025165167123
Jun 2025747445
Jul 2025330
Total435743802532